Immunome, Inc. (NASDAQ:IMNM) Receives Average Recommendation of “Buy” from Brokerages

Shares of Immunome, Inc. (NASDAQ:IMNM) have been assigned a consensus recommendation of “Buy” from the seven brokerages that are presently covering the stock, Marketbeat Ratings reports. Seven analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $29.80.

A number of brokerages have weighed in on IMNM. Guggenheim began coverage on Immunome in a research note on Monday, April 15th. They issued a “buy” rating and a $35.00 target price on the stock. JPMorgan Chase & Co. assumed coverage on Immunome in a research note on Tuesday, April 30th. They issued an “overweight” rating and a $24.00 target price on the stock. Wedbush reiterated an “outperform” rating and issued a $33.00 price objective on shares of Immunome in a report on Tuesday, May 14th. Finally, Piper Sandler assumed coverage on Immunome in a report on Friday, May 31st. They issued an “overweight” rating and a $27.00 price objective for the company.

Insider Transactions at Immunome

In related news, Director Jean Jacques Bienaime bought 2,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 21st. The stock was bought at an average cost of $13.57 per share, for a total transaction of $27,140.00. Following the acquisition, the director now directly owns 9,615 shares of the company’s stock, valued at approximately $130,475.55. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Company insiders own 8.60% of the company’s stock.

Institutional Investors Weigh In On Immunome

Several institutional investors have recently bought and sold shares of the stock. Redmile Group LLC boosted its holdings in Immunome by 26.0% during the 1st quarter. Redmile Group LLC now owns 4,889,554 shares of the company’s stock valued at $120,674,000 after acquiring an additional 1,010,139 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in Immunome by 113.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,245,673 shares of the company’s stock valued at $55,425,000 after acquiring an additional 1,194,451 shares during the period. Vanguard Group Inc. boosted its holdings in Immunome by 16.1% during the 1st quarter. Vanguard Group Inc. now owns 2,019,738 shares of the company’s stock valued at $49,847,000 after acquiring an additional 279,712 shares during the period. Janus Henderson Group PLC boosted its holdings in Immunome by 10.6% during the 1st quarter. Janus Henderson Group PLC now owns 1,538,414 shares of the company’s stock valued at $37,957,000 after acquiring an additional 146,943 shares during the period. Finally, Avidity Partners Management LP purchased a new stake in Immunome during the 4th quarter valued at about $14,268,000. 44.58% of the stock is currently owned by hedge funds and other institutional investors.

Immunome Stock Up 1.1 %

Shares of NASDAQ IMNM opened at $12.10 on Friday. The firm has a market capitalization of $725.64 million, a P/E ratio of -1.60 and a beta of 1.85. The stock’s 50-day simple moving average is $14.35 and its two-hundred day simple moving average is $17.00. Immunome has a twelve month low of $6.13 and a twelve month high of $30.96.

Immunome (NASDAQ:IMNM) last announced its earnings results on Tuesday, May 14th. The company reported ($0.34) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.46. The business had revenue of $1.03 million for the quarter, compared to analyst estimates of $4.00 million. Immunome had a negative return on equity of 37.33% and a negative net margin of 1,829.44%. As a group, research analysts anticipate that Immunome will post -1.45 EPS for the current fiscal year.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.